Are people with MS hypersensitive to medications due to increased blood brain permeability? Are they at increased risk to develop side effects to meds that don’t typically cross the BBB? What are the implications for medication administration?
How do people with MS under age 60 compare to those over 60 in terms of occurrence and type of co-morbidities, severity, age of onset, and related factors?
How many people on Tysabri experience a waning effect as they approach their next dose? How much does this effect impact their symptoms and quality of life?
More data/experience on ‘wearing off phenomenon’ with Ocrevus treatment. Can next infusion be administered at 5 months instead of 6 months to avoid this wearing off phenomenon?
